In the end, the data is what's going to get us somewhere. CDiddy was right a few posts back - this isn't the be all end all, and Fauci knows it, but it's better than nothing right now. They have clinical data, however wildly imperfect, from several hundred people. If it actually reduces the mortality rate by 3% (debatable) for the population receiving it... then the FDA should approve it immediately. No need to let perfect be the enemy of good.

However, once we generate data that shows compellingly that leronlimab provides significant benefit in a randomized, controlled, double-blinded clinical trial, I expect that the FDA should give CYDY the same treatment. If they don't, I'll be grabbing the pitchforks and shotguns. But until then, then FDA is doing exactly what I would expect here: acting incredibly quickly to allow drugs that have shown even marginal improvement to get to the public as fast as possible.

Remdesivir getting emergency approval with data like this is a benefit for CytoDyn and leronlimab. It sets a bar, and we expect to clear that bar like we're wearing moon shoes. If leronlimab works as well as our doctors think that it does, the sole thing that matters right now is enrolling the trials as fast as possible.